Showing 201-210 of 5234 results for "".
- Galderma's IL-31 Blocker Nemolizumab Wows in PNhttps://practicaldermatology.com/news/galdermas-il-31-blocker-nemolizumab-wows-in-pn/2461619/Galderma’s nemolizumab performed well in Prurigo Nodularis (PN). Nemolizumab is a first-in-class investigational monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31.Nemolizumab is an investigational drug and Galderma has not received approval for any indi…
- Game On: Level Ex, GladskinMD Introduce Battle of the Biomehttps://practicaldermatology.com/news/game-on-level-ex-gladskinmd-introduce-battle-of-the-biome/2461618/Level Ex is teaming up with Gladskin to create custom, interactive gaming experiences that educate and train medical professionals on the science of endolysin technology and Gladskin’s new product line. As its first collaboration, the companies created a game called Battle of the Biome. Leveragin…
- Guselkumab Shows Greater Treatment Persistence than IL-17s in Both Bio-naïve and Bio-experienced Psoriasis Patientshttps://practicaldermatology.com/news/guselkumab-shows-greater-treatment-persistence-than-il-17s-in-both-bio-naive-and-bio-experienced-psoriasis-patients/2461613/Tremyfa (guselkumab) may beat out other biologics when it comes to patient persistence, and a post-hoc analysis of guselkumab showed improvements in scalp psoriasis and quality-of-life measures at week 48. Research found that bio-experienced and bio-naïve psoriasis patients were more likely to sta…
- LEO Pharma Adds to Global Leadership Teamhttps://practicaldermatology.com/news/leo-pharma-adds-to-global-leadership-team/2461607/Dr. Jacob Pontoppidan Thyssen is the new Executive Vice President and Chief Scientific Officer for LEO Pharma’s Research and Early Development arm. The company announced that a significant shift in R&D to a research model in early 2023. The change aims to drive the early-stage pipeline with extern…
- National Society for Cutaneous Medicine Endorses Use of GEP Testing for Melanomahttps://practicaldermatology.com/news/national-society-for-cutaneous-medicine-endorses-use-of-gep-testing-for-melanoma/2461597/The National Society for Cutaneous Medicine now recommends use of gene expression profile (GEP) testing in the clinical assessment and management of cutaneous melanoma (CM). The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM patient manageme…
- Boehringer Ingelheim, FIT Join Forces to Raise GPP Awarenesshttps://practicaldermatology.com/news/boehringer-ingelheim-fit-join-forces-to-raise-gpp-awareness/2461581/Boehringer Ingelheim is teaming up with the Fashion Institute of Technology (FIT) in New York to extend The Unwearable Collection, a four-piece art collection that illustrates the physical and emotional burden of generalized pustular psoriasis (GPP). Over the course of the partnership, working in…
- Garnier Nutrisse Announces Drew Barrymore as Brand Ambassadorhttps://practicaldermatology.com/news/garnier-nutrisse-announces-drew-barrymore-as-brand-ambassador/2461577/Drew Barrymore is the new brand ambassador for Garnier Nutrisse, an expansion to her current role with the Garnier portfolio. Barrymore's role debuts with a creative campaign highlighting Garnier Nutrisse's new and improved Nourishing Color Crème formula for nourished hair and better color, featur…
- FDA Gives Nod to First Particulate Placental Extracellular Matrix Medical Device for Wound Managementhttps://practicaldermatology.com/news/fda-gives-nod-to-first-particulate-placental-extracellular-matrix-medical-device-for-wound-management/2461574/The U.S. Food and Drug Administration cleared Convatec’s InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The InnovaMatrix PD medical device joins Convatec’s existing InnovaMatrix AC product as the first and only next-generation placental-derived medi…
- Don't Forget Leprosy: Group Marks 150th Anniversary of Dr. Hansen's Discovery of M. lepraehttps://practicaldermatology.com/news/dont-forget-leprosy-group-marks-150th-anniversary-of-dr-hansens-discovery-of-m-leprae/2461573/The University of Bergen, Norway and Sasakawa Leprosy (Hansen's Disease) Initiative will mark the 150th anniversary of Dr. Gerhard Armauer Hansen's discovery of the leprosy bacillus, M. leprae, in 1873. They plan to hold an event in Bergen and launch a commemorative webcast on Feb. 28, 2023. Dr.…
- Kintor Pharma’s GT20029 Performs Well in Phase 1 Trial of Acne and Androgenetic Alopeciahttps://practicaldermatology.com/news/kintor-pharmas-gt20029-performs-well-in-phase-i-trial-of-acne-and-androgenetic-alopecia/2461559/Kintor Pharmaceutical Limited’s GT20029 was safe and well tolerated and had good pharmacokinetic characteristics in healthy people and people with androgenetic alopecia (AGA) or acne, according to a phase 1 clinical trial. GT20029 is the first topical PROTAC compound in the world that has complete…